Critical Comparison: Oramed Pharmaceuticals (ORMP) and Its Rivals

Oramed Pharmaceuticals (NASDAQ: ORMP) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Oramed Pharmaceuticals to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation.

Institutional & Insider Ownership

1.3% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.4% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 27.5% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oramed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -54.96% -29.63%
Oramed Pharmaceuticals Competitors -3,253.54% -94.81% -38.15%

Earnings and Valuation

This table compares Oramed Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Oramed Pharmaceuticals $640,000.00 -$10.96 million -9.46
Oramed Pharmaceuticals Competitors $216.80 million -$39.57 million -66.56

Oramed Pharmaceuticals’ competitors have higher revenue, but lower earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Oramed Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals’ competitors have a beta of 1.53, suggesting that their average share price is 53% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Oramed Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals 0 0 1 0 3.00
Oramed Pharmaceuticals Competitors 510 2421 6576 122 2.66

Oramed Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 175.33%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.95%. Given Oramed Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Oramed Pharmaceuticals is more favorable than its competitors.

Summary

Oramed Pharmaceuticals beats its competitors on 8 of the 12 factors compared.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply